Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33 results about "Cyclophilin A" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A 17-KDa cytoplasmic PEPTIDYLPROLYL ISOMERASE involved in immunoregulation. It is a member of the cyclophilin family of proteins that binds to CYCLOSPORINE.
Endometrium cancer diagnose reagent, reagent kit and controlling medicament
InactiveCN101261279AImprove survival rateAvoid harmMicrobiological testing/measurementBiological testingEndometrial cancerBiology (field)
The invention belongs to the field of the tumor molecule biology, in particular to a diagnosis reagent, a reagent knit and prevention and cure drugs of endometrial carcinoma, which provides a new diagnosis reagent and medicine for the early diagnosis and the prevention of endometrial carcinoma, and also provides a new method for filtering the medicine used for preventing endometrial carcinoma. The diagnosis reagent for endometrial carcinoma of the invention contains a reagent which can test the expressing level of a human cyclophilin A protein or the content of the mRNA of genes of the human cyclophilin A protein. The medicine which can prevent endometrial carcinoma of the invention includes: the expressing carrier of a shPNA molecule which can express the human cyclophilin A, etc. can change the expressing level of the human cyclophilin A protein or the mRNA content of the genes of the human cyclophilin A protein. The diagnosis reagent of the invention can be used for the early diagnosis of endometrial carcinoma, which has a wide application prospect.
Owner:SICHUAN UNIV
Diagnostic method for brain damage-related disorders
A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, selected from A-FABP, E-FABP, PGP 9.5, GFAP, Prostaglandin D synthase, Neuromodulin, Neurofilament L, Calcyphosine, RNA binding regulatory subunit, Ubiquitin fusion degradation protein 1 homolog, Nucleoside diphosphate kinase A, Glutathione S tranferase P, Cathepsin D, DJ-1 protein, Peroxiredoxin 5 and Peptidyl-prolyl cis-trans isomerase A (Cyclophilin A) in a sample of body fluid taken from the subject.
Owner:UNIVERSITY OF GENEVA +1
Immunogenic composition and method of developing a vaccine based on cyclophilin a binding site
InactiveUS20050214317A1Virus peptidesPharmaceutical delivery mechanismIMMUNE STIMULANTSMessenger RNA
Owner:NELSON M KARP M D
Lentiviral protein delivery system for rna-guided genome editing
The invention is directed to a system comprising a lentivirus vector particle which encodes at least one guide RNA sequence that is complementary to a first DNA sequence in a host cell genome, a Cas9 protein, and optionally a donor nucleic acid molecule comprising a second DNA sequence. The invention also is directed to a method of altering a DNA sequence in a host cell using such a system, where the host cell can be in a human and the altered DNA can be of the human β-globin gene. The invention also is directed to a fusion protein comprising a Cas9 protein and a cyclophilin A (CypA) protein. The invention also is directed to sequences of vectors that can be used in the system and method.
Owner:UNITED STATES OF AMERICA
Clone, expression and biological activity of stingray caudal spine cyclophilin A gene
InactiveCN1428348AGood application prospectHigh industrial development valueSugar derivativesMicrobiological testing/measurementCDNA libraryEscherichia coli
The present invention utilizes the construction of dasytis akajei caudal spine cDNA library and DNA sequencing and designs the primer according to the obtained (CyP) EST 3' end and carrier nucleotide sequence, and uses PCR method to screen the dasytis akajei caudal spine cDNA library and clone the cyclophilin A total strength gene. The tength of new gene is 656 bp for coding mature peptide of 167 amino acids, the isoelectric point of the expressed protein is 8.34, and the molecular weight is 18,021 Dalton. The dasytis akajei caudal spine cyclophilin A gene is cloned in the uxA gene 3' tail end of thioredoxing gene fusion expression vector pTRX and the fusion gene meeting reading frame is construcled, said fusion protein is existed in colibacillus, its expression amount can be up to 60 mg / L.
Owner:北京博奥环宇生物技术有限公司
N-(2,6-dibenzyloxy benzoyl)-N'-substituted urea compound and preparation method and application thereof
The invention relates to a novel N-(2,6-dibenzyloxy benzoyl)-N'-substituted urea compound and a preparation method and an application thereof. Structural general formula of the compound is shown as a formula (I), wherein R1 is a C5-C25 cyclic alkyl, aryl or heterocyclic group, or a substituted C1-C6 straight-chain or branch-chain alkyl (shown in the specification). The current study shows that cyclophilin A (CypA) participates in multiple physiological and pathological processes of a human body. Thus, the compound provided by the invention can be applied to preparation of a cyclophilin A (CypA) excitant or preparation of drugs used for preventing or treating diseases mediated by CypA.
Owner:EAST CHINA UNIV OF SCI & TECH
Neuroactive agents and methods of their use
InactiveUS20080145340A1Increasing CD14 receptor signallingBiocideSenses disorderMotor neurone diseaseCyclophilin A
This invention is related to a method of controlling neurodegeneration by increasing CD 147 receptor signaling. Neuroprotection can be achieved suing cyclophilin A or a functional variant, analog or derivative as a ligand for the CDE 147 receptor administered in various means including gene therapy. Conditions treatable with this method include cerebra ischemia, Alzheimer's Disease, Parkinson's Disease, Motor Neurone Disease and / or N=neuronal loss due to trauma and spinal cord damage.
Owner:UNIV OF WESTERN AUSTRALIA
Application of anti-BASIGIN humanized antibody in preparation of drugs for treating COVID-19
PendingCN111420048AInhibition of chemotaxisAchieve healingAntiviralsAntibody ingredientsReceptorHumanized antibody
The invention discloses an application of an anti-human BASIGIN humanized antibody in preparation of drugs for treating COVID-19. The amino acid sequence of a light chain variable region of the anti-human BASIGIN humanized antibody is shown as SEQ ID NO:1, and the amino acid sequence of a heavy chain is shown as SEQ ID NO:3; and the nucleotide sequence of the light chain variable region is shown as SEQ ID NO:2, and the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO:4. The antibody can specifically recognize and bind a virus invasion host epithelial cell co-receptor CD147, block the interaction of the CD147 and COVID-19 S protein, and interaction of the CD147 and cyclophilin A (CyPA), thereby inhibiting the COVID-19 from infecting host cells.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Diagnostic method for brain damage-related disorders
A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, selected from A-FABP, E-FABP, PGP 9.5, GFAP, Prostaglandin D synthase, Neuromodulin, Neurofilament L, Calcyphosine, RNA binding regulatory subunit, Ubiquitin fusion degradation protein 1 homolog, Nucleoside diphosphate kinase A, Glutathione S tranferase P, Cathepsin D, DJ-1 protein, Peroxiredoxin 5 and Peptidyl-prolyl cis-trans isomerase A (Cyclophilin A) in a sample of body fluid taken from the subject.
Owner:UNIVERSITY OF GENEVA +1
Methods and compositions for inhibiting cholesterol uptake
InactiveUS20070116645A1Compounds screening/testingPeptide/protein ingredientsCholesterol uptakeAnnexin
The present invention is directed to a method for the lowering of levels of LDL cholesterol in an individual comprising administering to the individual an agent which modulates the activity of the protein annexin 2, cyclophilin A, cyclophilin 40, or HSP 56 or the complex of annexin 2 and caveolin I, in the intestinal cells of the individual.
Owner:THOMAS JEFFERSON UNIV +1
Hybridoma cell, monoclonal antibody for anti-human cyclophilin A and application thereof
ActiveCN108893449AStable secretionSignificance of innovationAntipyreticAnalgesicsProtein.monoclonalProtein molecules
The inventio discloses a hybridoma cell, a monoclonal antibody for anti-human cyclophilin A and an application thereof. The invention adopts a traditional cell hybridoma preparation technique for acquiring a hybridoma cell strain for stably secreting the monoclonal antibody of the anti-human cyclophilin A (cyclophilin A, CypA). The preservation number of the hybridoma cell is CCTCC NO: C201126; the secreted antibody can specifically identify CypA protein molecules expressed in various tissues of a human body; and a new effective tool is provided for diagnosing and treating cancers and inflammations.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Method of examining mammary gland disease
ActiveUS20150192585A1Rapid identificationEfficient identificationDisease diagnosisPharmaceutical non-active ingredientsDiseaseBiology
The object of the present invention is to provide an early mastitis detection method that can detect mastitis easily and quickly when compared to the prior methods and also a biomarker to be used with the method.The object can be solved by a method of examining a mammary gland disease by using the level of cyclophilin A in a mammary gland or in milk as indicator. More specifically, the object can be a method of examining a mammary gland disease comprising steps (1) and (2) listed below;(1) a step of detecting cyclophilin A in the milk collected from an udder or an udder quarter of a subject and thereby determining the cyclophilin A level in the milk; and(2) a step of determining the onset of a mammary gland disease or the possibility of onset of a mammary gland disease in the udder or the udder quarter of the subject on the basis of the cyclophilin A level in the milk.
Owner:TOHOKU UNIV
Detection method of mammary gland disease
The object of the present invention is to provide an early mastitis detection method that can detect mastitis easily and quickly when compared to the prior methods and also a biomarker to be used with the method.The object can be solved by a method of examining a mammary gland disease by using the level of cyclophilin A in a mammary gland or in milk as indicator. More specifically, the object can be a method of examining a mammary gland disease comprising steps (1) and (2) listed below;(1) a step of detecting cyclophilin A in the milk collected from an udder or an udder quarter of a subject and thereby determining the cyclophilin A level in the milk; and(2) a step of determining the onset of a mammary gland disease or the possibility of onset of a mammary gland disease in the udder or the udder quarter of the subject on the basis of the cyclophilin A level in the milk.
Owner:TOHOKU UNIV
Methods, agents and peptides for inducing an innate immune response in HIV vaccination
ActiveUS9358281B2Relieve symptomsPrevents and alleviates symptomCompound screeningApoptosis detectionVaccinationImmune modulator
The present invention relates to enhancing, modulating or stimulating the innate immune response to HIV-1 and other viral pathogens and to the modulation and application of immune modulators and peptides for HIV-1 or other pathogen vaccines. The invention provides methods and means to activate an innate response to HIV-1 utilizing or via the HIV capsid protein or peptide, including modulating the binding of cyclophilin A to HIV capsid protein and modulating the ability of HIV to activate the major innate transcription factor IRF3 and interferon. Methods and assays are provided for screening for compounds, agents, or peptides capable of enhancing or activating innate immune response, particularly to HIV-1.
Owner:NEW YORK UNIV
Endometrium cancer diagnose reagent, reagent kit and controlling medicament
InactiveCN101261279BImprove survival rateAvoid harmMicrobiological testing/measurementBiological testingWilms' tumorMedicine use
The invention belongs to the field of the tumor molecule biology, in particular to a diagnosis reagent, a reagent knit and prevention and cure drugs of endometrial carcinoma, which provides a new diagnosis reagent and medicine for the early diagnosis and the prevention of endometrial carcinoma, and also provides a new method for filtering the medicine used for preventing endometrial carcinoma. The diagnosis reagent for endometrial carcinoma of the invention contains a reagent which can test the expressing level of a human cyclophilin A protein or the content of the mRNA of genes of the human cyclophilin A protein. The medicine which can prevent endometrial carcinoma of the invention includes: the expressing carrier of a shPNA molecule which can express the human cyclophilin A, etc. can change the expressing level of the human cyclophilin A protein or the mRNA content of the genes of the human cyclophilin A protein. The diagnosis reagent of the invention can be used for the early diagnosis of endometrial carcinoma, which has a wide application prospect.
Owner:SICHUAN UNIV
Kit for specific detection of endometrial cancer
InactiveCN105823879ALow costEasy to manufactureBiological material analysisSpecific detectionOncology
The invention discloses a kit for specifically detecting an endometrial cancer .Aptamer has good affinity with human Cyclophilin A protein .By means of the aptamer, Cyclophilin A protein in the blood can be trapped, the endometrial cancer is detected through changes of the content of the aptamer, and the aptamer is prepared into the corresponding kit to be used for endometrial cancer screening .The kit has the advantages of being high in sensitivity and low in cost.
Owner:李静
Clone, expression and biological activity of stingray caudal spine cyclophilin A gene
InactiveCN100509837CSugar derivativesMicrobiological testing/measurementEscherichia coliCDNA library
The present invention constructs red ray (Dasytis akajei) tail thorn cDNA library and DNA sequencing, and according to the obtained cyclophilin (CyP) EST 3' end and carrier nucleotide sequence, designs primers, uses the method of PCR, from The full-length cyclophilin A gene was screened and cloned from the red ray sting cDNA library. The length of the new gene is 656bp, and it encodes a mature peptide of 167 amino acids. The expressed protein has an isoelectric point of 8.34 and a molecular weight of about 18,021 Daltons. The red stingray thorn cyclophilin A gene was cloned at the 3' end of the trxA gene of the thioredoxin gene fusion expression vector pTRX, and a fusion gene in line with the reading frame was constructed. The fusion protein was soluble in E. coli as an intracellular Form exists, the expression amount can reach 60mg / L. Through Ni-Chelating affinity chromatography, protease 3C cleavage and gel filtration, the mature recombinant red ray cyclophilin A protein with a purity of more than 95% was obtained, with a yield of 10 mg / L. The protein has peptidylproline cis-trans isomerase activity.
Owner:北京博奥环宇生物技术有限公司
Method for testing for cardiovascular disease with cyclophilin A
ActiveUS9791461B2Easy to checkAvoid difficult choicesDisease diagnosisBiological testingExamination methodCyclophilin A
An object of the present invention is to provide a novel examination method for a cardiovascular disease. As means for achieving the object, provided is an examination method for a cardiovascular disease, the method including the steps of: measuring a concentration of cyclophilin A protein in a human blood sample; and determining a probability of development of a cardiovascular disease based on the measured concentration of cyclophilin A protein.
Owner:TOHOKU UNIV
Rotavirus-resistant drug acting target, building method and application method thereof
InactiveCN101863966AEasy and quick screeningEasy and fast designMicrobiological testing/measurementVirus peptidesRotavirus RNAReactive site
The invention discloses a Rotavirus-resistant drug acting target which is a composite three-dimensional structure model of interaction of rotavirus VP6 protein and human Cyclophilin A, wherein the functional zone of the VP6 protein is amino acid from 52th to 100th site and amino acid from 349th to 392th site, and the active site comprises Asn 53, Ala 348, Val 349, Ile 355 and Pro 363; and the functional zone of the Cyclophilin A is amino acid from 54th to150th site, and the active site comprises Arg 55, Gln 63, Lys 125 and Arg 148. The invention also discloses a building method and an application method of the target; and the target and the application method thereof can simply and fast screen or design a compound capable of blocking the interaction of the rotavirus VP6 protein and the human Cyclophilin A; the invention researches and develops a specificity Rotavirus-resistant drug which is efficient and harmfulless; and the building method of the target is favor of the building of acting targets of other drugs.
Owner:ARMY MEDICAL UNIV
Rotavirus-resistant drug acting target, building method and application method thereof
InactiveCN101863966BPromote new drug research and developmentPromote research and developmentMicrobiological testing/measurementVirus peptidesRotavirus RNAReactive site
Owner:ARMY MEDICAL UNIV
Kit for specific detection of endometrial cancer
InactiveCN105807054ALow costEasy to manufactureBiological material analysisBiological testingSpecific detectionBiology
Owner:李静
Kit for specific detection of endometrial cancer
InactiveCN105807068ALow costEasy to manufactureBiological material analysisBiological testingSpecific detectionBiology
Owner:李静
Kit for specific detection of endometrial cancer
InactiveCN105823895ALow costEasy to manufactureBiological material analysisBiological testingSpecific detectionOncology
The invention discloses a kit for specifically detecting an endometrial cancer .Aptamer has good affinity with human Cyclophilin A protein .By means of the aptamer, Cyclophilin A protein in the blood can be trapped, the endometrial cancer is detected through changes of the content of the aptamer, and the aptamer is prepared into the corresponding kit to be used for endometrial cancer screening .The kit has the advantages of being high in sensitivity and low in cost.
Owner:李静
Hybridoma cell, monoclonal antibody against human cyclophilin a and application thereof
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Kit for specific detection of endometrial cancer
InactiveCN105807069ALow costEasy to manufactureBiological material analysisBiological testingSpecific detectionBiology
Owner:李静
Kit for specific detection of endometrial cancer
InactiveCN105823894ALow costEasy to manufactureBiological material analysisBiological testingAptamerSpecific detection
The invention discloses a kit for specifically detecting an endometrial cancer .Aptamer has good affinity with human Cyclophilin A protein .By means of the aptamer, Cyclophilin A protein in the blood can be trapped, the endometrial cancer is detected through changes of the content of the aptamer, and the aptamer is prepared into the corresponding kit to be used for endometrial cancer screening .The kit has the advantages of being high in sensitivity and low in cost.
Owner:李静
Recombination cyclophilin A antibody, preparation method thereof, enzyme-linked immuno sorbent assay (ELISA) kit and cell strains
ActiveCN102702357BIncrease contentIncrease your chances of screeningImmunoglobulins against cell receptors/antigens/surface-determinantsTissue cultureElisa kitSorbent
The invention relates to a recombination cyclophilin A antibody, a preparation method thereof, an enzyme-linked immuno sorbent assay (ELISA) kit and cell strains. The problems that process conditions are complex, the specificity is poor, and protein immunological activity loss is large in the process of preparing the existing recombination cyclophilin A antibody are solved. Induced bacteria whichare purified or not purified immunize experiment animals, and a specific polyclonal antibody or a specific monoclonal antibody of the recombination cyclophilin A can be obtained through screening andpurification. The recombination cyclophilin A antibody is prepared through the preparation method. A solid phase carrier and a detection antibody in the ELISA kit contain the recombination cyclophilin A antibodies. The preparation method of the recombination cyclophilin A antibody has the advantages that the process conditions are simple, the specificity is good, the purification is simple, the protein immunological activity loss is less, and the operation is convenient.
Owner:伊艾博(武汉)科技股份有限公司
Kit for specific detection of endometrial carcinoma
InactiveCN105842446ALow costEasy to manufactureBiological material analysisBiological testingSpecific detectionCyclophilin A
Owner:李静
Application of cyclosporin A in preparing anti-rotavirus medicaments
InactiveCN101843893APoor resolutionSolve the problem of large toxic side effectsAntiviralsCyclic peptide ingredientsRotavirus RNAMedicine
The invention discloses the application of cyclosporin A in preparing of anti-rotavirus medicaments. by combining with human cyclophilin A, the cyclosporin A can block interaction of rotavirus VP6 protein and the human cyclophilin A, thereby inhibiting the formation of rotavirus particles to achieve the effect of resisting rotavirus. Adopting the cyclosporin A as an active ingredient, it is helpful to develop specific anti-rotavirus medicaments with high efficiency and low toxin.
Owner:ARMY MEDICAL UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com